复宏汉霖:授予Alvogen Korea汉斯状独家许可

GoldenOctober2024

金十数据4月25日讯,复宏汉霖公告,公司与Alvogen Korea Co., Ltd.订立许可协议,授予其在韩国独家商业化汉斯状(斯鲁利单抗注射液)的权利。根据协议,Alvogen Korea将支付首付款500万美元,监管里程碑付款不超过950万美元,商业销售里程碑款项不超过9750万美元,以及基于年度净销售额18%至25%不等的比例计算的分层特许权使用费。许可协议自签署日起生效,初始有效期至许可产品首次商业化销售之日起10周年届满。

Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to Disclaimer.
Opmerking
0/400
Geen opmerkingen